Lead Compound

Type: Keyphrase
Name: Lead Compound
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Arno Licenses U. Minn. Technology to Identify Likeliest Onapristone Patients

Arno Therapeutics said today it licensed from the University of Minnesota a cancer diagnostic technology designed to identify patients most likely to benefit from Arno's lead compound, a drug candidate now in a Phase I study.The technology is related ... [Published Genetic Engineering News - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Minerva Neurosciences to Present at Baird 2014 Health Care Conference

CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Minerva NeurosciencesA live audio webcast of the presentation will be available online from the investor relations section of the company's website at http://ir.minervaneurosciences.com. A replay of ... [Published BusinessWeek - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Celldex Offers A Broad Portfolio Of Oncology Solutions

By Scrying Biotech :While it's hard to take a company seriously that affectionately refers to its lead product candidates by the nicknames, Rindo, Glemba and Varli, Celldex Therapeutics (NASDAQ: CLDX ), headquartered in Hampton, NJ with research facilities ... [Published BioPortfolio - Aug 25 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 1 reports

Turning Car Batteries into Solar Cells

Lead has quite a history as the soft metal once saw many uses, such as water pipes to additives for gasoline and paint, but is now restricted to just a few, due to its potential health hazards. That is also why we see so many recycling programs specifically ... [Published Overclockers Club - Aug 19 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Santhera Receives CHF 13.4 Million Through Sale of Treasury Shares

The treasury shares with a par value of CHF 1.00 were issued from the Company`s conditional capital. The newly issued shares represent 4.1% of the Company`s total outstanding share capital of CHF 4,911,728."This additional capital provides us with a strong ... [Published Pettinga Financial Advisors - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 2 reports

$4.1M in NIAID funding should carry BioCryst’s hemorrhagic fever drug into human studies

US BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), adeveloper of small molecule drugs, said Wednesday it had received anadditional USD 4.1 million (EUR 3.1m) from the National Institute ofAllergy and Infectious Diseases (NIAID) to advance the developmentof ... [Published MedCity News - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 3 reports

Conatus Pharmaceuticals' (CNAT) CEO Steven Mento on Q2 2014 Results - Earnings Call Transcript

OperatorWelcome to the Conatus Pharmaceuticals Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investor Center of the Conatus website at conatuspharma.com. This call is ... [Published Seeking Alpha - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Lipocine: An Undervalued Biotech With An Approaching Catalyst

Summary Lipocine's Phase III results for its lead compound LPCN-1021 are expected to be announced in the third quarter of 2014. LPCN-1021 could be the first and only oral testosterone replacement therapy indicated for low testosterone in the U.S. LPCN-1021 ... [Published Seeking Alpha - Aug 13 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Scientist invests in biotech stocks

Bjarke Krysel Christensen is a scientist with a specialization in microbiology (the study of microscopic organisms). He has invested in biotechnology stocks for more than two decades. Mr. Christensen’s investment approach is to use his scientific knowledge ... [Published Globe and Mail - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Minerva Neurosciences Reports Second Quarter 2014 Financial Results

– Advanced Lead Compound MIN-101 in Phase 2 Studies for Schizophrenia and Clinical Development of MIN-202 in Insomnia –– Management to host conference call today at 4:30 p.m. ET –CAMBRIDGE, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, ... [Published EMoneyDaily - Aug 07 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 2 reports

Portage unit obtains U.S. patent for GAD treatment

Dr. Greg Bailey reportsPORTAGE'S BIOHAVEN GRANTED UNITED STATES PATENT FOR GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERSPortage Biotech Inc. investment Biohaven Pharmaceutical Holding Co.Ltd., where the company holds approximately 54-per-cent ... [Published Stockwatch - Aug 06 2014]
First reported Jul 22 2014 - Updated Jul 23 2014 - 3 reports

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ... [Published EON Science - Jul 22 2014]

Quotes

...as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell," said TSRI Professor Matthew Disney. "Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways."
...stable over the past 6 weeks, last week brought the highest weekly increase of the outbreak so far in all three of the hardest-hit countries. "This highlights the urgent need to reinforce control measures and increase capacity for case management" the WHO said
According to the news editors, the research concluded: "This is a potential lead compound for the development of drugs that could reduce the residual risk associated with elevated plasma TGs in dyslipidemia."
...In contrast, the Indian molecule has been found to be safe in animal studies. "Even a dosage of 2 gm per kg body weight has been found safe" said Vishwakarma

More Content

All (164) | News (94) | Reports (0) | Blogs (57) | Audio/Video (0) | Fact Sheets (1) | Press Releases (12)
sort by: Date | Relevance
Scripps Florida scientists make diseased cells ... [Published EurekAlert! - 14 hours ago]
Top five biotech SMEs in Europe announced [Published EuropaBio - Sep 01 2014]
Senegal's first Ebola case has links to Guinea [Published Centre For Infectious Disease Research and Policy - Aug 29 2014]
Arno Licenses U. Minn. Technology to Identify L... [Published Genetic Engineering News - Aug 29 2014]
Berg and the Pursuit of the Body's Hidden Drugs [Published Bio-IT World - Aug 28 2014]
Minerva Neurosciences to Present at Baird 2014 ... [Published BusinessWeek - Aug 28 2014]
MINERVA NEUROSCIENCES : to Present at Baird 201... [Published 4 Traders - Aug 28 2014]
Data from Tallinn University of Technology Adva... [Published HispanicBusiness.com - Aug 27 2014]
Piramal Enterprises to stop early-stage research [Published Business Standard India - Aug 27 2014]
Cellceutix Completes Enrollment in Phase 2b Cli... [Published Drugs.com - Aug 27 2014]
Himalayan plant may hold key to arthritis cure [Published Deccan Herald - Aug 26 2014]
Celldex Offers A Broad Portfolio Of Oncology So... [Published BioPortfolio - Aug 25 2014]
Celldex Offers A Broad Portfolio Of Oncology So... [Published Seeking Alpha - Aug 25 2014]
New Amsterdam Sciences Continues Pact With Dr. ... [Published Myrtle Beach Sun News - Aug 21 2014]
UC Begins to Look at Breast Cancer Drugs to Tre... [Published University of Cincinnati - Aug 21 2014]
European Patent Office Intention to Grant Sulfa... [Published Noodls - Aug 19 2014]
Turning Car Batteries into Solar Cells [Published Overclockers Club - Aug 19 2014]
Evaluation of Antimalarial Activity and Toxicit... [Published Plosone.org - Aug 19 2014]
Cellceutix Completes Enrollment in Phase 2b Cli... [Published Nasdaq - Aug 19 2014]
Cellceutix Completes Enrollment in Phase 2b Cli... [Published The CW11 - Aug 19 2014]
Cocrystal Pharma Reports Second Quarter Financi... [Published Yahoo! Finance - Aug 15 2014]
August 15, 2014: Santhera Receives CHF 13.4 Mil... [Published Noodls - Aug 15 2014]
Santhera Receives CHF 13.4 Million Through Sale... [Published Pettinga Financial Advisors - Aug 15 2014]
Santhera Receives CHF 13.4 Million Through Sale... [Published SPi World News - Aug 15 2014]
Santhera Receives CHF 13.4 Million Through Sale... [Published Franklin Credit Management Corporation - Aug 15 2014]
FDA Approval of Ceritinib for the Treatment of ... [Published The ASCO Post - Aug 15 2014]
Arno Therapeutics Reports Second Quarter 2014 F... [Published Town Hall - Aug 14 2014]
Conatus Pharmaceuticals' (CNAT) CEO Steven Ment... [Published Seeking Alpha - Aug 14 2014]
Conatus Pharmaceuticals Reports Second Quarter ... [Published Virtual Strategy Magazine - Aug 13 2014]
Conatus Pharmaceuticals Reports Second Quarter ... [Published CW Atlanta - Aug 13 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Phosphatidic acid promotes remyelination [Published Multiple Sclerosis Research - Aug 12 2014]
Yamamoto S, Gotoh M, Kawamura Y, Yamashina K, Yagishita S, Awaji T, Tanaka M, Maruyama K, Murakami-Murofushi K, Yoshikawa K. Cyclic phosphatidic acid treatment suppress cuprizone-induced demyelination and motor dysfunction in mice. Eur J Pharmacol. 2014. ...
SAGE Therapeutics Receives Fast Track Designati... [Published EON Science - Jul 22 2014]
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ...
SAGE Therapeutics Receives Fast Track Designati... [Published Business Wire Science: Science News - Jul 22 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ...
SAGE Therapeutics Receives Fast Track Designati... [Published Business Wire Health News - Jul 22 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ...
Resolve Initiates Phase 2 Clinical Study in SLE [Published PR Newswire: Health - Jul 16 2014]
SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE). Following the successful completion ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Rich Pharmaceuticals Hires Contract Research Or... [Published GlobeNewswire: Advertising News - Jul 23 2014]
Nora Therapeutics Presents Phase 1 Data on NT10... [Published GlobeNewswire: Advertising News - Jun 30 2014]
Cara Therapeutics Announces Appointment of Robe... [Published GlobeNewswire: Advertising News - Jun 24 2014]
Flexion Therapeutics Announces Positive Topline... [Published GlobeNewswire: Acquisitions News - Jun 17 2014]
TetraLogic Pharmaceuticals Announces Conference... [Published GlobeNewswire: Advertising News - Jun 13 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.